News
Public · Published
Boston Scientific Reports Q3 2026 Sales of $5.14 Billion, Adjusted EPS of $0.73
Boston Scientific reported third-quarter 2026 net sales of $5.14 billion, up 1.5% from a year earlier, with adjusted earnings per share of $0.73 versus $0.75 previously. The company lowered its full-year 2026 outlook to about 4.25% reported sales growth and adjusted earnings per share of $3.16 to $3.18.
Published:
Updated:
What happened
Boston Scientific reported third-quarter 2026 net sales of $5.14 billion, up 1.5% from a year earlier, with adjusted earnings per share of $0.73 versus $0.75 previously. The company lowered its full-year 2026 outlook to about 4.25% reported sales growth and adjusted earnings per share of $3.16 to $3.18.
Confirmed
Global impact / market context
Slower sales growth and lower profit per share than a year earlier suggest the company is selling more but keeping less profit, while the cut to its full-year outlook tells investors management now expects weaker results ahead, which can pressure the stock and reduce confidence in future earnings.
Analyst inference
Growth was uneven by region and business: U.S. sales rose just 0.5% and APAC fell 0.6%, while LACA grew 16.0%, and MedSurg expanded only 0.6%. This mix matters because slower high-growth segments can limit future revenue and profit, shaping how investors value the shares.
Analyst inference
What to watch
- Watch whether fourth-quarter sales and adjusted earnings per share land within the lowered full-year guidance of about 4.25% reported sales growth and $3.16 to $3.18 per share, since missing it would further weaken confidence. Confirmed
- Watch for updates on the Elite AF trial, which evaluates a Boston Scientific device, because trial progress could affect future product revenue and how investors judge the company's research pipeline. Proposed
- Watch U.S. and APAC sales trends, since U.S. growth of 0.5% and APAC decline of 0.6% were the weakest regions and could keep overall revenue growth below the company's historical pace. Analyst inference
Evidence
- Original source link unavailable